@article{6c1861aa53c74e4d94bf737e1b2f9102,
title = "Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics",
abstract = "There is a paucity of data regarding outcomes and response to standard therapy in patients with limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) who harbor MYC rearrangement (MYC-R) with or without BCL2 and/or BCL6 rearrangements. We conducted a multicenter retrospective study of MYC-R LS-ABCL patients who received either rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), or more intensive immunochemotherapy (IIC) plus or minus consolidative involved-field radiation therapy (IFRT). One hundred four patients from 15 academic centers were included. Forty four patients (42%) received R-CHOP, of whom 52% had IFRT. Sixty patients (58%) received IIC, of whom 40% had IFRT. Overall response rate was 91% (84% complete response [CR]; 7% partial response). Patients with double-hit lymphoma (DHL; n = 40) had a lower CR rate compared with patients with MYC-R only (75% vs 98%; P = .003). CR rate was higher in the IFRT vs no-IFRT group (98% vs 72%; P<.001). Median follow-up was 3.2 years; 2-year progression-free survival (PFS) and overal survival (OS) were 78% and 86% for the entire cohort, and 74% and 81% for the DHL patients, respectively. PFS and OS were similar across treatment groups (IFRT vs no IFRT, R-CHOP vs IIC) in the entire cohort and in DHL patients. Our data provide a historical benchmark for MYC-R LS-ABCL and LS-DHL patients and show that outcomes for this population may be better than previously recognized. There was no benefit of using IIC over R-CHOP in patients with MYC-R LS-ABCL and LS-DHL.",
author = "Pallawi Torka and Kothari, {Shalin K.} and Suchitra Sundaram and Shaoying Li and Medeiros, {L. Jeffrey} and Ayers, {Emily C.} and Landsburg, {Daniel J.} and Bond, {David A.} and Maddocks, {Kami J.} and Anshu Giri and Brian Hess and Pham, {Luu Q.} and Ranjana Advani and Yang Liu and Barta, {Stefan Klaus} and Vose, {Julie M.} and Churnetski, {Michael C.} and Cohen, {Jonathon B.} and Madelyn Burkart and Reem Karmali and Joanna Zurko and Amitkumar Mehta and Olszewski, {Adam J.} and Sarah Lee and Hill, {Brian T.} and Burns, {Timothy F.} and Frederick Lansigan and Emma Rabinovich and David Peace and Adrienne Groman and Kristopher Attwood and Hernandez-Ilizaliturri, {Francisco J.}",
note = "Funding Information: This work was supported by a biostatistics shared resource supported by a Roswell Park Comprehensive Cancer Center support grant from the National Institutes of Health, National Cancer Institute (P30CA016056). Funding Information: Conflict-of-interest disclosure: K.J.M. has received research support from Bristol-Myers Squibb, Merck, Pharmacyclics, and Novartis, and has been an advisory board member for Pharmacy-clics, Celgene, Teva, Seattle Genetics, AstraZeneca, and Bayer. R.K. has received research support from Kite/Gilead, Celgene/ Juno, Takeda, and Bristol-Myers Squibb; has been an advisory board member for Kite/Gilead and Celgene/Juno; and has been on speakers{\textquoteright} bureaus for Kite/Gilead and AstraZeneca. A.J.O. has received research support from Genentech/Roche, Spectrum Pharmaceuticals, and TG Pharmaceuticals. B.H. has received research support and consulting remuneration from Genentech. D.P. has equity holdings in Bristol-Myers Squibb and Merck, and has received associate research funding from Celgene and ER Squibb and Sons. The remaining authors declare no competing financial interests. Publisher Copyright: {\textcopyright} 2020 by The American Society of Hematology.",
year = "2020",
month = jan,
day = "28",
doi = "10.1182/bloodadvances.2019000875",
language = "English (US)",
volume = "4",
pages = "253--262",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "2",
}